

# REGAL

INVESTMENT FUND

The Manager  
Company Announcement Office  
Australian Securities Exchange Limited  
Exchange Centre  
Level 4, 20 Bridge Street  
Sydney NSW 2000

---

25 March 2025

## INVESTMENT PORTFOLIO UPDATE

Equity Trustees Limited (ACN 004 031 298, AFSL 240975) as the Responsible Entity for Regal Investment Fund (ASX:RF1) wishes to provide an update to investors regarding a portfolio holding in Opthea Limited ('OPT'), an ASX and Nasdaq-listed global biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases.

On 24 March 2025, OPT announced the receipt of negative topline results for the first of two Phase 3 clinical trials of lead drug candidate OPT-302. As a result of this development, OPT has requested that trading in its listed securities remain suspended on the ASX and Nasdaq until Monday, 31 March 2025.

By way of update to RF1 shareholders, Regal Funds Management Pty Ltd (the Investment Manager of RF1) wishes to advise the total OPT position size in aggregate, prior to OPT's announcement, was approximately 5.6%.

Should you have any questions regarding this notice or RF1 more generally, please don't hesitate to contact MUFG Pension & Market Services, as Registry provider for RF1, at [regalfund@cm.mpms.mufg.com](mailto:regalfund@cm.mpms.mufg.com) or alternatively Regal Funds Management at [investorrelations@regalfm.com](mailto:investorrelations@regalfm.com).

Yours sincerely,

Andrew Godfrey  
Director

Equity Trustees Limited (ACN 004 031 298, AFSL 240975) as the Responsible Entity for RF1



*Mr. Andrew Godfrey, Director, has authorised that this document be given to the ASX*